Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anaerostipes caccae
- Development stage
- Unknown
- Lead developer
- Clostrabio
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Anaerostipes caccae* is a next-generation probiotic and live biotherapeutic product consisting of a specific strain of lactate-utilizing, butyrate-producing anaerobic bacteria. Developed by Clostrabio (as CLB101), it is designed to restore gut microbiome balance and metabolic functions, specifically butyrogenesis. In the context of food allergies and inflammatory conditions like ulcerative colitis, it acts by cross-feeding with lactic acid bacteria (such as *Weizmannia coagulans*) to convert lactate into butyrate. Butyrate is a critical short-chain fatty acid that supports intestinal barrier integrity and modulates immune responses. The product is positioned as a dietary supplement for gut microbiome support in infants and adults with food allergies and dysbiosis.
- Brand names
- CLB101CLB-101CLB 101
- Other names
- Anaerostipes caccae
Beyond the preview
Go deeper on Anaerostipes caccae.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anaerostipes caccae.